

KERYX BIOPHARMACEUTICALS INC
 Form 4
 April 20, 2006

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
WEISS MICHAEL S

(Last) (First) (Middle)

C/O KERYX
 BIOPHARMACEUTICALS,
 INC., 750 LEXINGTON AVE

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
**KERYX
 BIOPHARMACEUTICALS INC
 [KERX]**

3. Date of Earliest Transaction
 (Month/Day/Year)
 04/18/2006

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
 Chariman and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(D)	Price	
Common Stock	04/18/2006		M		40,000	A	\$ 1.3 55,000	D
Common Stock	04/18/2006		S ⁽¹⁾		1,000	D	\$ 17.254 54,000	D
Common Stock	04/18/2006		S ⁽¹⁾		3,000	D	\$ 17.12 51,000	D
Common Stock	04/18/2006		S ⁽¹⁾		1,000	D	\$ 17.114 50,000	D

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.11	49,000	D
Common Stock	04/18/2006	<u>S(1)</u>	10,500	D	\$ 17.1	38,500	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.0943	37,500	D
Common Stock	04/18/2006	<u>S(1)</u>	5,500	D	\$ 17.09	32,000	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.083	31,000	D
Common Stock	04/18/2006	<u>S(1)</u>	2,000	D	\$ 17.08	29,000	D
Common Stock	04/18/2006	<u>S(1)</u>	500	D	\$ 17.072	28,500	D
Common Stock	04/18/2006	<u>S(1)</u>	500	D	\$ 17.07	28,000	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.0683	27,000	D
Common Stock	04/18/2006	<u>S(1)</u>	4,000	D	\$ 17.06	23,000	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.056	22,000	D
Common Stock	04/18/2006	<u>S(1)</u>	500	D	\$ 17.052	21,500	D
Common Stock	04/18/2006	<u>S(1)</u>	2,500	D	\$ 17.05	19,000	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.04	18,000	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.0334	17,000	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.03	16,000	D
Common Stock	04/18/2006	<u>S(1)</u>	1,000	D	\$ 17.0621	15,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Options (Right to Buy)	\$ 1.3	04/18/2006		M	40,000 ⁽²⁾	12/23/2003 ⁽³⁾ 12/24/2012	Common Stock	40,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
WEISS MICHAEL S C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVE NEW YORK, NY 10022	X		Chariman and CEO	

Signatures

/s/ Michael S.
Weiss

04/20/2006

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The shares of common stock were sold pursuant to Mr. Weiss' Rule 10b5-1 trading plan with a brokerage firm dated December 30, 2005.
- (2) The options were exercised pursuant to Mr. Weiss' Rule 10b5-1 trading plan with a brokerage firm dated December 30, 2005.
- (3) All options have vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.